Cargando…

Onabotulinum Toxin A Intradetrusor Injections in Children with Neurogenic Lower Urinary Tract Dysfunction: Long-Term Histological Effects on the Bladder Wall

Background: In the last twenty-five years, Onabotulinum Toxin A (BTX-A) has gained increasing popularity for neurogenic lower urinary tract dysfunction (NLUTD) treatment. To maintain its efficacy, repeated BTX-A intradetrusor injections are required over time, with unknown effects on the bladder wal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pellegrino, Chiara, Forlini, Valentina, Lena, Federica, Capitanucci, Maria Luisa, Diomedi Camassei, Francesca, Castelli, Enrico, Mosiello, Giovanni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216107/ https://www.ncbi.nlm.nih.gov/pubmed/37238971 http://dx.doi.org/10.3390/biomedicines11051300

Ejemplares similares

Intradetrusor Injections of Onabotulinum Toxin-A in Children With Urinary Incontinence due to Neurogenic Detrusor Overactivity Refractory to Antimuscarinic Treatment
por: Tarcan, Tufan, et al.
Publicado: (2014)

Outcomes of Intradetrusor Onabotulinum Toxin A Therapy in Overactive Bladder Refractory to Sacral Neuromodulation
por: Trinh, Hamilton, et al.
Publicado: (2019)

Onabotulinum Toxin A (Botox®) in the Treatment of Neurogenic Bladder Overactivity
por: Rohrsted, Malene, et al.
Publicado: (2012)

Posterior urethral valves: Role of prenatal diagnosis and long-term management of bladder function; a single center point of view and review of literature
por: Pellegrino, Chiara, et al.
Publicado: (2023)

Home pelvic floor exercises in children with non‐neurogenic Lower Urinary Tract Symptoms: Is fitball an alternative to classic exercises?
por: Sollini, Maria Laura, et al.
Publicado: (2022)

Editorial Comment: Intradetrusor botulinum toxin injections (300 units) for the treatment of poorly compliant bladders in patients with adult neurogenic lower urinary tract dysfunction
por: Averbeck, Marcio Augusto
Publicado: (2021)

Editorial Comment: Solifenacin treatment after intradetrusor injections with botulinum toxin in patients with neurogenic detrusor overactivity
por: Averbeck, Marcio Augusto
Publicado: (2022)

Preserved micturition after intradetrusor onabotulinumtoxinA injection for treatment of neurogenic bladder dysfunction in Parkinson’s disease
por: Knüpfer, Stephanie C., et al.
Publicado: (2016)

Predictors of Response to Intradetrusor Botulinum Toxin-A Injections in Patients with Idiopathic Overactive Bladder
por: Cohen, Brian L., et al.
Publicado: (2009)

Intradetrusor botulinum toxin type A in refractory overactive bladder: A potential future treatment
por: Mahajan, Rajiv, et al.
Publicado: (2011)

Efficacy and safety of intradetrusor onabotulinumtoxinA injection for managing paediatric non-neurogenic overactive bladder: A prospective case-series study
por: El-Dakhakhny, Amr S., et al.
Publicado: (2019)

Time of onset and factors associated with delayed response post intradetrusor injection of onabotulinumtoxin a in patients with neurogenic and idiopathic overactive bladder syndrome
por: Al-Shaiji, Tariq Faisal, et al.
Publicado: (2023)

Real-World Evaluation of the Tolerability to Onabotulinum Toxin A: The RETO Study
por: García-Azorín, David, et al.
Publicado: (2022)

Onabotulinum toxin A in the treatment of chronic migraine: patient selection and special considerations
por: Barbanti, Piero, et al.
Publicado: (2017)

The Role of Onabotulinum Toxin Type A in the Management of Chronic Non-migraine Headaches
por: Jia, Cassie, et al.
Publicado: (2019)

AB204. Repeated intradetrusor botulinum toxin type A injections are still effective for patients with neurogenic detrusor overactivity secondary to spinal cord injury in China
por: Chen, Hui, et al.
Publicado: (2016)

Onabotulinum toxin A vs. incobotulinum toxin A for the treatment of chronic migraine: a retrospective review
por: Lucchese, Scott, et al.
Publicado: (2023)

Bladder diverticuli following injection of onabotulinum toxin A in a patient with multiple sclerosis and autosomal dominant polycystic kidney disease
por: Raza, Syed Imran, et al.
Publicado: (2018)

Botulinum Toxin-A Therapy in Pediatric Urology: Indications for the Neurogenic and Non-Neurogenic Neurogenic Bladder
por: Dyer, Lori, et al.
Publicado: (2009)

Urinary tract infection in the neurogenic bladder
por: Vigil, Humberto R., et al.
Publicado: (2016)

Reduced versus standard intradetrusor OnabotulinumtoxinA injections for treatment of overactive bladder
por: DiCarlo‐Meacham, Angela M., et al.
Publicado: (2022)

Antibiotic prophylaxis may not be necessary in patients with asymptomatic bacteriuria undergoing intradetrusor onabotulinumtoxinA injections for neurogenic detrusor overactivity
por: Leitner, Lorenz, et al.
Publicado: (2016)

EHMTI-0278. Onabotulinum toxin a for hemicrania continua: a case series of 8 patients
por: Miller, S, et al.
Publicado: (2014)

Onabotulinum toxin-A (Botox) for spastic equinus in cerebral palsy: a prospective kinematic study
por: Hastings-Ison, T., et al.
Publicado: (2018)

Further Evidence that Onabotulinum Toxin is a Viable Treatment Option for Pediatric Chronic Migraine Patients
por: Ali, Sameer S, et al.
Publicado: (2019)

New Injection Points of Onabotulinum Toxin A for Spastic Paralysis of the Fingers: Eight Cases of Report
por: Yamada, Shoko Merrit, et al.
Publicado: (2020)

Efficacy of Onabotulinum Toxin A on Obsessive–Compulsive Traits in a Population of Chronic Migraine Patients
por: Viticchi, Giovanna, et al.
Publicado: (2022)

The role of botulinum toxin A in treating neurogenic bladder
por: Weckx, Filip, et al.
Publicado: (2016)

Interventions to improve tolerability of local anesthetic intradetrusor Botulinum toxin injections: A systematic review
por: Faure Walker, Nicholas, et al.
Publicado: (2022)

Intradetrusor OnabotuliniumtoxinA injection for refractory bladder spasms before vesicovaginal fistula repair
por: Sirls, Evan, et al.
Publicado: (2022)

Neurogenic Bowel Dysfunction in Children and Adolescents
por: Mosiello, Giovanni, et al.
Publicado: (2021)

Evaluation of the effect of 100U of Onabotulinum toxin A on detrusor contractility in women with idiopathic OAB: A multicentre prospective study
por: De Rienzo, Gaetano, et al.
Publicado: (2021)

Editorial Comment: Long-term outcomes and risks factors for failure of intradetrusor onabotulinumtoxin A injections for the treatment of refractory neurogenic detrusor overactivity
por: Averbeck, Marcio Augusto
Publicado: (2021)

Effectiveness and Safety of Intradetrusor OnabotulinumtoxinA Injection for Neurogenic Detrusor Overactivity and Overactive Bladder Patients in Taiwan—A Phase IV Prospective, Interventional, Multiple-Center Study (Restore Study)
por: Wang, Chung-Cheng, et al.
Publicado: (2021)

von Brunn's Nests and Follicular Cystitis Following Intradetrusor OnabotulinumtoxinA Injections for Overactive Bladder
por: Nekkanti, Silpa, et al.
Publicado: (2017)

Pelvic-Spinal Analysis and the Impact of Onabotulinum toxin A Injections on Spinal Balance in one Child With Cerebral Palsy
por: Chaléat-Valayer, Emmanuelle, et al.
Publicado: (2016)

Protocol for a prospective observational study of cortical lower urinary tract control changes following intradetrusor injection of botulinum toxin-A in patients with multiple sclerosis
por: Elizondo, Rodolfo A, et al.
Publicado: (2017)

Pharmacotherapy in Pediatric Neurogenic Bladder Intravesical Botulinum Toxin Type A
por: Sager, Cristian, et al.
Publicado: (2012)

Does Reduction of Number of Intradetrusor Injection Sites of aboBoNTA (Dysport(®)) Impact Efficacy and Safety in a Rat Model of Neurogenic Detrusor Overactivity?
por: Huynh Le Maux, Amélie, et al.
Publicado: (2015)

Comparison of intravesical instillation of hyaluronic acid with intradetrusor botulinum toxin A injection or cystoscopic hydrodistention for ketamine-associated cystitis
por: Li, Bingkun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_sf1d88fb9t4v1420trmj3j1515